Treatment Options

The treatment and management of COVID-19 patients are evolving rapidly. There is a global effort to discover novel treatments and test existing therapies that are safe and effective.

This week Fred Goldstein and I discuss what medical treatments are available for patients who contract SARS-CoV-2 and develop symptoms of COVID19 and discuss the latest insights into what is working and what has been shown in recent WHO SOLIDARITY trial to offer no advantage (Remdesivir, Hydroxychloroquine, Lopinavir, and Interferon)

While the FDA has authorized a lot of EUA diagnostic tools there are only 3 EUA’s for treatment:

1. Convalescent Plasma
2. Remdesivir
3. GammaCore SapphireTM CV from electroCore

The second is showing now effect per the WHO SOLIDARITY trial (run in 405 hospitals across 30 countries and with 11,266 adults randomized to treatment) leaving two potential treatments and until we can develop in the coming months

Want to learn more you can join the free webinar taking place October 28 at 11:00 am ET

Hosted by David Shulkin, MD, 9th Secretary of Veterans Affairs, who is joined by

• Jennifer Pena, MD, Medical Director for Global Executive Medicine and former Physician to Vice President of the United States
• Sten Lindahl, MD, PhD, FRCA,  Chair Emeritus of the Nobel Committee in Physiology of Medicine
• Paul Currier, MD, MPH Director of the Respiratory Care Unit at Massachusetts General Hospital
• Peter Staats, MD, Chief Medical Officer Chief Medical Officer, electroCore, Inc.

A Q&A with participants will follow.

Tagged as AI, Clinical Trial, Contact Tracing, Convalescent Plasma, COVID-19, COVID19, COVID_19, GammaCore SapphireTM CV, Masks, Remdesivir, SARS-CoV-2, Science, WHO